1、 VERDECCHIA P, REBOLDI G, ANGELI F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention[J]. Hypertension, 2005, 46(2): 386-392. VERDECCHIA P, REBOLDI G, ANGELI F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention[J]. Hypertension, 2005, 46(2): 386-392.
2、 王祥瑞. 吸入麻醉药物的药理特性及应用[J]. 上海医学, 2009, 32(1):7-8. 王祥瑞. 吸入麻醉药物的药理特性及应用[J]. 上海医学, 2009, 32(1):7-8.
3、 孙佳凤, 刘增慧, 杜伯祥,等. 七氟醚麻醉与丙泊酚麻醉对腹部手术患者血管内皮糖萼降解影响的比较[J]. 中华麻醉学杂志, 2019, 39(7):801-804. 孙佳凤, 刘增慧, 杜伯祥,等. 七氟醚麻醉与丙泊酚麻醉对腹部手术患者血管内皮糖萼降解影响的比较[J]. 中华麻醉学杂志, 2019, 39(7):801-804.
4、 李玉倩, 郑宏, 俞瑾,等. 七氟醚后处理在再灌注早期心肌保护作用[J]. 临床心血管病杂志, 2017, 33(11):1054-1057. 李玉倩, 郑宏, 俞瑾,等. 七氟醚后处理在再灌注早期心肌保护作用[J]. 临床心血管病杂志, 2017, 33(11):1054-1057.
5、 胡利国, 方才, 朱运莲. 丙泊酚靶控输注全麻诱导时BIS值与机体应激反应的关系[J]. 临床麻醉学杂志, 2007, 23(7):560-562. 胡利国, 方才, 朱运莲. 丙泊酚靶控输注全麻诱导时BIS值与机体应激反应的关系[J]. 临床麻醉学杂志, 2007, 23(7):560-562.
6、 WANG J, LUO L, ZHAO S, et al. Low intensity extracorporeal shockwave therapy shifts PDE5i nonresponders to responders[J]. Int Braz J Urol, 2020, 46(6): 934-942. WANG J, LUO L, ZHAO S, et al. Low intensity extracorporeal shockwave therapy shifts PDE5i nonresponders to responders[J]. Int Braz J Urol, 2020, 46(6): 934-942.
7、 SARDAR P, KUNDU A, BISCHOFF M, et al. Hybrid coronary revascularization versus coronary artery bypass grafting in patients with multivessel coronary artery disease: a meta-analysis[J]. Catheter Cardiovasc Interv, 2018, 91(2): 203-212. SARDAR P, KUNDU A, BISCHOFF M, et al. Hybrid coronary revascularization versus coronary artery bypass grafting in patients with multivessel coronary artery disease: a meta-analysis[J]. Catheter Cardiovasc Interv, 2018, 91(2): 203-212.
8、 MALIK A H, SHETTY S, KAR K, et al. Effect of β-blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis[J]. J Geriatr Cardiol,2019(3):291-297. MALIK A H, SHETTY S, KAR K, et al. Effect of β-blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis[J]. J Geriatr Cardiol,2019(3):291-297.
9、 RODRIGUEZ J B C, ALKHATEEB H. Beta-blockers, calcium channel blockers, and mortality in stable coronary artery disease[J]. Curr Cardiol Rep, 2020, 22(3): 1-5. RODRIGUEZ J B C, ALKHATEEB H. Beta-blockers, calcium channel blockers, and mortality in stable coronary artery disease[J]. Curr Cardiol Rep, 2020, 22(3): 1-5.
10、 傅向华,孙家安.美国心脏病学会和心脏协会修订版慢性稳定型心绞痛的处理指南[J]. 临床荟萃,2004(3):124-127. 傅向华,孙家安.美国心脏病学会和心脏协会修订版慢性稳定型心绞痛的处理指南[J]. 临床荟萃,2004(3):124-127.
11、 GRUNDY S M. Management of high serum cholesterol and related disorders in patients at risk for coronary heart disease[J]. Am J Med, 1997, 102(2): 15-22. GRUNDY S M. Management of high serum cholesterol and related disorders in patients at risk for coronary heart disease[J]. Am J Med, 1997, 102(2): 15-22.
12、 LIU X, PENG D, WANG Y, et al. Diagnostic accuracy of Chinese medicine diagnosis scale of phlegm and blood stasis syndrome in coronary heart disease: a study protocol[J]. Chin J Integr Med, 2019, 25(7): 515-520. LIU X, PENG D, WANG Y, et al. Diagnostic accuracy of Chinese medicine diagnosis scale of phlegm and blood stasis syndrome in coronary heart disease: a study protocol[J]. Chin J Integr Med, 2019, 25(7): 515-520.
13、 马骏, 刘同涛, 贾崇奇. 中老年患者心血管病危险因素与冠状动脉病变程度的相关性分析[J]. 中华老年医学杂志, 2011, 30(1):42-45. 马骏, 刘同涛, 贾崇奇. 中老年患者心血管病危险因素与冠状动脉病变程度的相关性分析[J]. 中华老年医学杂志, 2011, 30(1):42-45.
